



Contacts: Tularik Inc.
Andrew J. Perlman, M.D., Ph.D.
650-825-7000

Burns McClellan, Inc.
Stephanie Diaz (Media)
415-352-6262
John Nugent (Investors)
212-213-0006

For Immediate Release

National Cancer Institute Supports Tularik Cancer Genomics

South San Francisco, CA – June 21, 2000 – Tularik Inc. (NASDAQ: TLRK) today announced that it has been awarded a Small Business Innovation Research (SBIR) grant from the National Cancer Institute of the National Institutes of Health. This Phase I grant, entitled “Antibodies to New Amplified Breast Cancer Gene Products”, supports research to create antibodies to novel amplified breast cancer gene products that will be used for immunochemical assays.

Tularik utilizes Representational Difference Analysis (RDA), a proprietary technique, in combination with other technology to discover cancer genes (oncogenes) that are amplified at the DNA level. The ultimate goal of this project is to discover and develop small molecule therapeutics that block the cancer-promoting effect of these amplified genes.

“This grant recognizes the value of Tularik’s genomic technologies for therapeutic and diagnostic applications,” stated David V. Goeddel, Ph.D., Chief Executive Officer of Tularik. “Our genomics approach, which focuses on the identification of primary genetic alterations underlying cancer, holds great promise for developing improved diagnostics and treatments for cancer.”

The NIH awards SBIR grants to biotechnology companies for technologically innovative projects that can convert cutting-edge biomedical research into new technology breakthroughs and new products that can benefit public health.

-more-

Tularik is engaged in the discovery and development of a broad range of novel and superior orally available drugs based on gene regulation. Tularik programs address cancer, CMV, diabetes, obesity, inflammation, allergy/asthma, lipid disorders and bacterial diseases, and a class of targets known as orphan nuclear receptors. Tularik has established strategic partnerships with Japan Tobacco Inc., Roche Bioscience and Knoll AG. For additional information, visit Tularik's Internet website at www.tularik.com.

Statements in this press release that are not strictly historical are "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. There can be no assurance that Tularik will obtain necessary regulatory approvals for its drug candidates or be able to develop a commercially viable pharmaceutical product. These and other risks are more fully discussed in Tularik's SEC reports, including the report on Form 10-Q for the quarter ended March 31, 2000.

###